Hims Q1 Guidance Reveals ~$65M GLP-1 Headwind, Short Interest at 34% Points to Squeeze Risk

What happened

Hims & Hers guided Q1 2026 revenue to $600–625 million, below the $616–650 million Street consensus, citing an approximately $65 million headwind from its shift away from compounded GLP-1s. GAAP EPS is expected to collapse roughly 83% year-over-year to about $0.03, confirming that the margin reset from the branded transition is already embedded in current estimates. Short interest remains elevated at approximately 34% of the float, implying two to three days to cover and raising the potential for a sharp squeeze if the company delivers on its branded transition timeline. The DeepValue report had already flagged that the compounded-to-branded bridge is the critical swing factor, with the WAIT rating dependent on evidence that branded Ozempic/Wegovy access stabilizes revenue per subscriber. This Q1 guidance confirms that the near-term financial impact is material, but the elevated short interest suggests that any positive surprise on execution could trigger outsized upside.

Implication

The near-term pain is now quantified, yet the bull case hinges on whether the branded transition is completed quickly enough to prevent a deeper erosion of revenue and margins in subsequent quarters. Investors should wait for the Q1 10-Q to assess the new 'Monthly Revenue per Average Subscriber' KPI before adding exposure.

Thesis delta

The Q1 guidance clarifies the immediate revenue drag from the GLP-1 pivot, increasing the probability of the bear case (30% implied value $18) if the branded ramp stalls. However, the high short interest means the market may be overly pessimistic on execution; a clean transition could trigger a squeeze. This does not alter the fundamental WAIT rating but sharpens the near-term catalyst: Q1 results will either confirm the bear narrative or ignite a squeeze.